Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19

Razzaq，Aroona1; Disoma，Cyrollah1,2; Zhou，Yuzheng1,3; Tao，Siyi1; Chen，Zongpeng1; Liu，Sixu1; Zheng，Rong1; Zhang，Yongxing1; Liao，Yujie1; Chen，Xuan1; Liu，Sijie1; Dong，Zijun1; Xu，Liangtao1; Deng，Xu4; Li，Shanni1; Xia，Zanxian1,5,6,7

2024

10.1002/rmv.2500

Reviews in Medical Virology   影响因子和分区

1052-9276

1099-1654

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously producing new variants, necessitating effective therapeutics. Patients are not only confronted by the immediate symptoms of infection but also by the long-term health issues linked to long COVID-19. Activation of epidermal growth factor receptor (EGFR) signalling during SARS-CoV-2 infection promotes virus propagation, mucus hyperproduction, and pulmonary fibrosis, and suppresses the host's antiviral response. Over the long term, EGFR activation in COVID-19, particularly in COVID-19-induced pulmonary fibrosis, may be linked to the development of lung cancer. In this review, we have summarised the significance of EGFR signalling in the context of SARS-CoV-2 infection. We also discussed the targeting of EGFR signalling as a promising strategy for COVID-19 treatment and highlighted erlotinib as a superior option among EGFR inhibitors. Erlotinib effectively blocks EGFR and AAK1, thereby preventing SARS-CoV-2 replication, reducing mucus hyperproduction, TNF-α expression, and enhancing the host's antiviral response. Nevertheless, to evaluate the antiviral efficacy of erlotinib, relevant clinical trials involving an appropriate patient population should be designed.

COVID-19 EGFR inhibitor epidermal growth factor receptor (EGFR) activation erlotinib lung cancer pulmonary fibrosis SARS-CoV-2

SCI

英语

其他

MICROBIOLOGY

2-s2.0-85180252452

Scopus

1.Department of Cell Biology,School of Life Sciences,Central South University,Changsha,China
2.Department of Biology,College of Natural Sciences and Mathematics,Mindanao State University,Marawi City,Philippines
3.Institute for Hepatology,National Clinical Research Center for Infectious Disease,Shenzhen Third People's Hospital,Southern University of Science and Technology,Shenzhen,China
4.Xiangya School of Pharmaceutical Science,Central South University,Changsha,China
5.Hunan Key Laboratory of Animal Models for Human Diseases,School of Life Sciences,Central South University,Changsha,China
6.Hunan Key Laboratory of Medical Genetics,School of Life Sciences,Central South University,Changsha,China
7.Centre for Medical Genetics,School of Life Sciences,Central South University,Changsha,China

Razzaq，Aroona,Disoma，Cyrollah,Zhou，Yuzheng,et al. Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19[J]. Reviews in Medical Virology,2024,34(1).

Razzaq，Aroona.,Disoma，Cyrollah.,Zhou，Yuzheng.,Tao，Siyi.,Chen，Zongpeng.,...&Xia，Zanxian.(2024).Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19.Reviews in Medical Virology,34(1).

Razzaq，Aroona,et al."Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID-19".Reviews in Medical Virology 34.1(2024).